PET/MRI shows inflammation link to mitral valve prolapse
Researchers using a hybrid PET/MRI scanner detected a link between degenerative...Read more on AuntMinnie.comRelated Reading:
4 core applications of cardiovascular 3D printing
Cardiac ultrasound at bedside boosts disease diagnosis
ACC: Echocardiography identifies patients for valve repair
Right heart quantification awareness: Part 6 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 1, 2020 Category: Radiology Source Type: news
Outcomes Similar After TAVR in Bicuspid, Tricuspid Anatomy
WEDNESDAY, May 27, 2020 -- All-cause mortality and stroke are comparable at 30 days and one year after transcatheter aortic valve replacement (TAVR) among patients with bicuspid and tricuspid valve stenosis, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2020 Category: Pharmaceuticals Source Type: news
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
IRVINE, Calif., May 18, 2020 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has ... Devices, Interventional, Cardiology, Regulatory Edwards Lifesciences, PASCAL transcatheter valve, tricuspid regurgitation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 18, 2020 Category: Pharmaceuticals Source Type: news
What Is a Percutaneous Valve Replacement Procedure?
Title: What Is a Percutaneous Valve Replacement Procedure?Category: Procedures and TestsCreated: 5/14/2020 12:00:00 AMLast Editorial Review: 5/14/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - May 14, 2020 Category: Cardiology Source Type: news
How Dangerous Is Percutaneous Heart Valve Replacement Surgery?
Title: How Dangerous Is Percutaneous Heart Valve Replacement Surgery?Category: Procedures and TestsCreated: 5/14/2020 12:00:00 AMLast Editorial Review: 5/14/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - May 14, 2020 Category: Cardiology Source Type: news
Best Practices for Human-Centric Design of Medical Devices
Medical devices designed to accommodate human variability present a growing opportunity for the healthcare and life sciences industries. Historically, medicine has solved many of the “simple†issues first: how to fix a broken leg has been known for centuries! But today we have treatments that didn’t even exist a generation ago, such as the use of stents and replacement valves for heart disease. These devices address a more limited cohort of people and are most successful when designed to be patient-specific. The cohorts themselves must also be further defined to account...
Source: MDDI - May 5, 2020 Category: Medical Devices Authors: Kristian Debus Tags: Design Source Type: news
CT helps predict TAVR outcomes
Identifying fibrotic lung disease on CT before transcathetor aortic valve replacement...Read more on AuntMinnie.comRelated Reading:
4D CT sheds light on post-TAVR treatment strategies
3D printing technique improves heart valve sizing
3D-printed aortas could work well for TAVR
3D printing helps evaluate leaks after TAVR procedures
CT better than echo for aortic annulus before TAVR (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 4, 2020 Category: Radiology Source Type: news
Medtech in a Minute: Another Deal Bites the Dust, Telemedicine Changes the Game, and More
Another Deal Bites the Dust
Citing a negative market impact from COVID-19, Alphatec backed out of its agreement to acquire EOS Imaging. While the deal is no longer feasible as contemplated, Alphatec said it is open to a strategic collaboration, if EOS is willing. Earlier this month, Organovo killed a proposed merger with Tarveda Therapeutics, but not because of the pandemic. That decision was prompted by indecisive scientific data on Organovo's part.
Telemedicine Is Changing the Diabetes Game
Telemedicine is emerging as the hero technology during COVID-19. In the diabetes space, the technology is enabling new patient acces...
Source: MDDI - April 30, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Edwards Lifesciences Drops 2020 Revenue Guidance Due to COVID-19
While Edwards Lifesciences reported first-quarter sales growth of 14%, the structural heart company saw a steep drop in procedure volume in the last few weeks of the quarter due to COVID-19.
"As you might expect, procedure volumes in March varied greatly by geography, even by hospital, as patients and providers turned their focus to the pandemic," CEO Mike Mussallem said during the company's first-quarter earnings call, according to a SeekingAlpha transcript.
Mussallem said the company expects the impact of COVID-19 on its transcatheter aortic valve replacement (TAVR) sales to be most severe in the second quarter, followed...
Source: MDDI - April 25, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news
Catheter-Based Solution Being Developed to Treat Heart Valve Calcification
Pi-Cardia Ltd. has raised $27 million to develop a catheter-based solution to treat heart valve calcification. The Rehovot, Israel-based company said the financing was led by Sonfinnova Partners and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing investors.
The financing follows the successful completion of the company’s First-In-Human studies of the Leaflex Catheter.
Pi-Cardia said its technology performs mechanical scoring of valve calcification, restoring leafelts’ mobility and improving valve hemodynamics. The company...
Source: MDDI - April 20, 2020 Category: Medical Devices Authors: MDDI Staff Tags: Business Cardiovascular Source Type: news
PET/CT pinpoints Hodgkin's lymphoma treatment response
PET/CT significantly outperformed CT alone in predicting treatment response...Read more on AuntMinnie.comRelated Reading:
FDG-PET leads prediction on neuroendocrine tumor outcomes
IMV: PET scan volume continues growing at steady pace
FDG-PET/CT points to cervical cancer patient outcomes
FDG-PET/CT within a year of heart valve surgery looks safe
PET/CT beats SPECT for neuroendocrine tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 20, 2020 Category: Radiology Source Type: news
Low-Risk TAVR Loses Ground at 2 Years in PARTNER 3 Low-Risk TAVR Loses Ground at 2 Years in PARTNER 3
Transcatheter aortic valve replacement (TAVR) continued to show superiority over surgical replacement at 2 years ' follow-up, but between-group differences narrowed considerably.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 16, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Abbott's TriClip(TM) Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition
New system offers a proven safe and effective minimally invasive non-surgical solution
The TriClip Syst... Devices, Interventional, Cardiology, Regulatory Abbott, TriClip, Transcatheter, Tricuspid Valve Repair, Tricuspid Valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 9, 2020 Category: Pharmaceuticals Source Type: news
Abbott's TriClip ™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
- CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition (Source: Abbott.com)
Source: Abbott.com - April 9, 2020 Category: Pharmaceuticals Source Type: news
TAVR equivalent to surgery at 2 years among low-risk patients
(American College of Cardiology) Patients undergoing transcatheter aortic valve replacement (TAVR) fared equally well compared with those undergoing open heart valve replacement surgery in terms of the combined risk of death, stroke or rehospitalization at two years, the primary endpoint of the PARTNER 3 trial being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
